NEW YORK – Investment bank BTIG has initiated coverage of Fulgent Genetics with a Buy rating and a $20 price target.
In a research note on Thursday, BTIG analyst Sung Ji Nam wrote that Fulgent has shown growth over the past several years.
NEW YORK – Investment bank BTIG has initiated coverage of Fulgent Genetics with a Buy rating and a $20 price target.
In a research note on Thursday, BTIG analyst Sung Ji Nam wrote that Fulgent has shown growth over the past several years.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.